Maha Kosa
Pfizer (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Chemical Synthesis and Analysis, Monoclonal and Polyclonal Antibodies Research, Advanced Breast Cancer Therapies, HIV Research and Treatment
Most-Cited Works
- → Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease(1997)619 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements(1999)189 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics(2002)142 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics(2003)115 cited
- → AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies(1996)89 cited
- → Impact of Acid‐Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH‐Dependent Solubility, With Different Food Intake Conditions(2017)78 cited
- → Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease(1996)70 cited
- → Bis Tertiary Amide Inhibitors of the HIV-1 Protease Generated via Protein Structure-Based Iterative Design(1996)30 cited
- → Abstract 4515: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers(2015)5 cited
- → Abstract LB-196: A phase I open-label, fixed-sequence, two-period crossover study of the effect of multiple doses of Itraconazole on Palbociclib (PD–0332991) pharmacokinetics in healthy volunteers(2016)3 cited